Efficacy and Safety of Darolutamide in Combination with Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Darolutamide in Combination with Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer from the Phase III ARANOTE Trial Academic Background Metastatic hormone-sensitive prostate cancer (mHSPC) is a common type of prostate cancer. Patients typically respond to androgen-deprivation therapy (ADT) for a period of ti...

Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients with Newly Diagnosed Prostate Cancer

Using Cell Cycle Risk Score to Predict the Benefit of Radiotherapy Combined with ADT in Newly Diagnosed Prostate Cancer Patients Background Prostate cancer is one of the most common cancers among men globally. In terms of treatment, localized prostate cancer is often treated primarily with radiotherapy (RT). However, the efficacy of RT alone is oft...